According to Achillion Pharmaceuticals, it is estimated that over 150 million people around the world are infected with the hepatitis C virus (HCV). Most people infected with HCV go undiagnosed and it has become a major global health threat.
In light of this, I was pleased to hear about the announcement Achillion Pharmaceuticals made last week. Achillion announced that interim results from their phase 2a clinical trial were accepted for presentation at the EASL — American Association for the Study of Liver Diseases (AASLD) Special Conference: New Perspectives in Hepatitis C Virus Infection — The Roadmap for Cure to be held in Paris, France. According to Achillion, “This phase 2a study aims to establish the safety, pharmacokinetics and efficacy of doublet and triplet regimens, consisting of odalasvir and AL-335 with or without simeprevir, in treatment naïve patients with genotype 1 HCV infection for treatment durations of eight weeks or less.”
You can read the full announcement from Achillion here: